Pressmeddelande

BioStock: First patient dosed in Spago’s phase I/IIa trial

Cision Publicerad: 14 Dec 2023 09:46

Spago Nanomedical recently received approval to start the phase I/IIa study with Tumorad in Australia. The study is now well on its way as the company announced last week that the first patient has been successfully dosed. BioStock reached out to Spago's Chief Development Officer Paul Hargreaves to learn more.

Read the interview with Paul Hargreaves at biostock.se:

First patient dosed in Spago’s phase I/IIa trial - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Spago Nanomedical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!